What tirzepatide costs in Germany

Tirzepatide is sold in Germany under the brand name Mounjaro, manufactured by Eli Lilly. It holds a full EU marketing authorisation^[1] granted by the European Medicines Agency on 15 September 2022. That means it is not a grey-market compound: it sits on the shelves of licensed German pharmacies and can be prescribed by any German-licensed physician. What you actually pay, however, depends almost entirely on one question: are you insured under the statutory health insurance scheme (gesetzliche Krankenversicherung, GKV), do you have private insurance (private Krankenversicherung, PKV), or are you paying out of pocket?

This article breaks down the German pricing landscape for Mounjaro as of mid-2026, the reimbursement decisions that shape it, the AMNOG benefit-assessment process behind those decisions, and what patients can do to find out whether they qualify for coverage. This is editorial content, not medical or financial advice. Prices change; verify current figures with your pharmacy or insurer before acting on them.

Cash price at a German pharmacy (Selbstzahler)

If you have a prescription and no insurer willing to cover the cost, you pay the pharmacy retail price in full. Mounjaro is available in six weekly injection pen doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Each pack contains four pens, covering one month of treatment. In mid-2026, German pharmacy retail prices for a four-pen Mounjaro pack vary with dose; entry-level (2.5 mg) packs have been priced in the range of roughly 250 to 290 euros per month, with higher doses running toward 350 to 400 euros per month.

These are indicative ranges drawn from the German pharmacy market. Because Mounjaro does not sit in a Festbetrag (reference-price group) under SGB V § 35^[3], individual pharmacy pricing can vary. The Festbetrag mechanism, which caps what GKV pays for groups of therapeutically comparable medicines, does not apply to tirzepatide at this point because Mounjaro is still in the AMNOG negotiation cycle. Retail prices at licensed German pharmacies (Apotheken) are regulated by the Arzneimittelpreisverordnung (AMVV) pharmacy pricing ordinance, which sets margins but does not fix a single national retail price for all products.

A note on comparison shopping: German law permits licensed online pharmacies registered with BfArM to dispense prescription medicines. Registered EU online pharmacies display the EU safety logo. Some offer marginally different prices for non-reimbursed medicines, though for a GKV patient whose insurer covers the drug, the out-of-pocket difference is small (the standard prescription co-pay applies regardless of whether the pharmacy is a physical or online one).

GKV reimbursement: what statutory health insurance covers

Roughly 90 percent of the German population holds statutory health insurance. For GKV patients, access to a prescription medicine is governed first by whether the drug is on the reimbursable medicines list and second by the outcome of the AMNOG benefit-assessment process. New medicines entering the German market must submit benefit-assessment dossiers to the Gemeinsamer Bundesausschuss (G-BA)^[5] under the procedure established in SGB V § 35a^[2]. The G-BA assesses the additional clinical benefit relative to an appropriate comparator therapy. The outcome of that assessment then drives the price negotiations between the manufacturer and the GKV's umbrella negotiating body (GKV-Spitzenverband).

For the type 2 diabetes indication, Mounjaro has been subject to G-BA benefit assessment since its EU approval. Following assessment, tirzepatide is generally reimbursable for GKV patients with insufficiently controlled type 2 diabetes who are prescribed it according to the approved indication and guideline criteria. In practical terms, a GKV patient prescribed Mounjaro for type 2 diabetes by an endocrinologist or GP pays only the standard prescription co-pay, typically in the range of 5 to 10 euros per prescription item, which is the ceiling set by SGB V for most reimbursed medicines. The insurer covers the rest.

For the weight-management indication (obesity or overweight with comorbidities), the picture is more restricted. Germany's GKV has historically not reimbursed medicines prescribed solely for obesity, absent a concurrent diagnosis such as type 2 diabetes that falls within an approved indication. The G-BA's benefit assessment for the weight-management indication has proceeded under AMNOG, but reimbursement for obesity without comorbid T2D has not been broadly available under GKV as of mid-2026. Patients whose primary diagnosis is obesity, without type 2 diabetes, are more likely to need a private prescription and pay out of pocket or seek PKV coverage.

GKV policy on obesity medication can shift: individual health funds (Krankenkassen) sometimes run selective contracts (Selektivvertraege) with manufacturers that expand access beyond the standard G-BA framework. It is worth asking your specific Krankenkasse whether any such arrangement exists for Mounjaro.

What the G-BA and AMNOG process determined

AMNOG (Arzneimittelmarktneuordnungsgesetz), codified in SGB V § 35a^[2], requires that pharmaceutical manufacturers submit an evidence dossier to the G-BA at first market entry and again when new indications are approved. The G-BA has three months to complete its benefit assessment and publish findings. The assessment classifies the added benefit as: major added benefit (erheblicher Zusatznutzen), considerable added benefit (betraechtlicher Zusatznutzen), minor added benefit (geringer Zusatznutzen), non-quantifiable added benefit (nicht quantifizierbarer Zusatznutzen), no proven added benefit (kein Zusatznutzen nachgewiesen), or less benefit (Schaden).

The G-BA's assessment for tirzepatide in type 2 diabetes found non-quantifiable added benefit for certain patient subgroups, meaning the evidence pointed toward benefit but was insufficient in scope or data quality to quantify a magnitude. That classification is meaningful for the pricing negotiation: it places tirzepatide above medicines where no benefit is found, but does not generate the pricing weight that a 'major added benefit' classification would. Following the G-BA decision, GKV-Spitzenverband and Eli Lilly negotiated a reimbursement price. The negotiated price differs from the list pharmacy retail price; GKV pays a rebate-adjusted rate that is not publicly disclosed in full.

For GKV patients, this pricing architecture means the insurer absorbs the gap between the negotiated rate and the list price. The patient sees only the co-pay.

Private health insurance (PKV)

About 10 percent of the German population holds private health insurance (PKV). PKV insurers are required to cover medicines approved for a given indication when they are medically necessary, subject to the specific policy terms. For Mounjaro prescribed for an approved indication (type 2 diabetes, or weight management with the qualifying BMI and comorbidity profile), PKV typically covers the prescription cost, with any deductibles or cost-sharing applying per the individual policy terms.

PKV patients should verify with their insurer whether the weight-management indication is covered under their specific contract, as policy language on obesity medications varies between insurers and between policy generations. Some older PKV contracts explicitly exclude medicines prescribed for weight loss; newer contracts may differ. If your PKV has a tariff that includes a Beihilfe component (as is common for civil servants), the applicable federal or state Beihilfe schedule also determines coverage.

How to check whether you qualify for GKV reimbursement

The starting point is a consultation with your GP (Hausarzt) or specialist (Facharzt), most commonly an endocrinologist (Endokrinologe) or diabetologist (Diabetologe) for a type 2 diabetes indication, or an obesity specialist (Adipositaszentrum) for the weight-management indication. Physicians in Germany know the current reimbursement rules for their therapeutic area and can advise whether a GKV prescription is likely to be approved or whether you will need to apply for coverage through your Krankenkasse.

If your Krankenkasse rejects reimbursement, you have the right to appeal the decision (Widerspruch) in writing within four weeks. GKV patients in Germany have appeal rights under SGB V. A prescriber who believes the drug is medically necessary can support an appeal with clinical documentation. If you are in a situation where cost is the primary obstacle, your physician can also apply for individual case coverage (Einzelfallentscheidung) in some circumstances.

For current pack prices and availability, ask your pharmacy directly. For the regulatory framework for tirzepatide in Germany more broadly, including import rules and grey-market risks, see the tirzepatide Germany import rules article. For the full peptide and clinical profile, including the mechanism, trial data, and cross-country regulatory summary, see the tirzepatide overview page. For a comparison of weight-loss medicines available in Germany, see the GLP-1 receptor agonists overview.

What we do not yet know

AMNOG negotiations are ongoing and price-sensitive: the GKV-Spitzenverband and Eli Lilly may renegotiate rebate terms. The obesity indication benefit assessment and reimbursement negotiation may produce a broader GKV coverage pathway over the next one to two years, as political and regulatory pressure on obesity as a disease category grows across EU member states. We will update this page when the G-BA publishes new assessment decisions affecting tirzepatide.

The Zepbound brand (used in the US for the weight-management indication) has not launched in Germany or the EU as of mid-2026. The EU-wide brand remains Mounjaro for both indications.

Disclaimer

This article is for educational and journalistic purposes only. It does not constitute medical advice, financial advice, or a recommendation to seek or avoid any medicine. Mounjaro (tirzepatide) is a prescription-only medicine in Germany. Consult a licensed healthcare provider before starting any medication. Prices quoted are indicative ranges drawn from published market data as of mid-2026 and may change. Verify current prices and reimbursement status with your pharmacy or health insurer. PeptideMethods.com does not sell, distribute, or facilitate the sale of any pharmaceutical product.